Table 3.

Herbal preparation use and estrogen, PR and her2neu receptor status, and histology (adjusted ORs, 95% CI from polytomous logistic regression)

Total number of cases n (%)Cases* ever HEP use n (%)OR (95% CI)OR per year of use (Ptrend)
3,462 (100)
Receptor status
    ER positive2,542 (79.4)171 (6.7)0.74 (0.62-0.89)0.97 (0.07)
    ER negative661 (20.6)49 (7.4)0.68 (0.50-0.93)0.94 (0.11)
    PR positive2,144 (67.0)148 (6.9)0.77 (0.64-0.93)0.98 (0.30)
    PR negative1,057 (33.0)72 (6.8)0.66 (0.51-0.85)0.91 (0.01)
    HER2neu negative2,335 (71.7)164 (6.9)0.75 (0.62-0.90)0.97 (0.09)
    HER2neu positive593 (20.3)43 (7.3)0.73 (0.53-1.02)0.98 (0.48)
Histology
    Ductal invasive2,227 (64.4)156 (7.0)0.72 (0.60-0.87)0.97 (0.11)
    Lobular, mixed ductal/lobular, or tubular invasive921 (26.6)62 (6.7)0.76 (0.58-1.01)0.92 (0.03)
    Carcinoma in situ205 (5.9)25 (12.2)1.34 (0.86-2.09)1.01 (0.90)
Duration of HEP use (categories)
Ductal invasive
    <1 y31 (1.4)0.66 (0.44-0.98)
    1-5 y92 (4.1)0.72 (0.57-0.91)
    >5 y32 (1.4)0.76 (0.51-1.13)
Lobular, mixed ductal/lobular, or tubular invasive
    <1 y22 (2.4)1.17 (0.73-1.87)
    1-5 y31 (3.4)0.65 (0.45-0.96)
    >5 y9 (1.0)0.61 (0.30-1.21)

Models adjusted for region, year of birth, past and current hormone use, age at menopause, age at menarche, number of pregnancies (≥28th wk), breastfeeding, benign breast disease, number of mammograms, family history of breast cancer, occupational status, and sport (see footnote of Table 2 for categories).

  • *Numbers of controls in all models as shown in Table 2 for the total group.

  • Missing values for ER (n = 55), PR (n = 56), Her2neu (n = 329).